Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its target price lowered by Cantor Fitzgerald from $290.00 to $205.00 in a research note published on Tuesday morning,Benzinga reports. The firm currently has a neutral rating on the biopharmaceutical company’s stock.
ALNY has been the topic of a number of other reports. Chardan Capital decreased their price objective on shares of Alnylam Pharmaceuticals from $425.00 to $375.00 and set a “buy” rating on the stock in a research note on Friday, October 30th. Sanford C. Bernstein cut Alnylam Pharmaceuticals from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $376.00 to $199.00 in a research note on Friday, October 30th. TD Cowen reduced their target price on Alnylam Pharmaceuticals from $482.00 to $354.00 and set a “buy” rating on the stock in a report on Friday, October 30th. Morgan Stanley decreased their price target on Alnylam Pharmaceuticals from $300.00 to $240.00 and set an “equal weight” rating on the stock in a research note on Friday, October 30th. Finally, Bank of America reiterated a “buy” rating and issued a $287.00 price target (down from $460.00) on shares of Alnylam Pharmaceuticals in a research note on Friday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and eleven have given a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $287.57.
Read Our Latest Research Report on ALNY
Alnylam Pharmaceuticals Price Performance
ALNY stock opened at $147.82 on Tuesday. The company’s 50-day moving average price is $210.88 and its two-hundred day moving average price is $272.20. The firm has a market cap of $19.80 billion, a P/E ratio of 7.67 and a beta of 0.42. The company has a quick ratio of 2.43, a current ratio of 2.48 and a debt-to-equity ratio of 0.18. Alnylam Pharmaceuticals has a 12 month low of $146.51 and a 12 month high of $479.79.
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $16.26 earnings per share for the quarter, topping analysts’ consensus estimates of $1.66 by $14.60. Alnylam Pharmaceuticals had a net margin of 52.85% and a return on equity of 155.33%. The company had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.43 billion. During the same quarter in the prior year, the firm posted $2.90 EPS. The firm’s quarterly revenue was up 16.7% on a year-over-year basis. On average, analysts anticipate that Alnylam Pharmaceuticals will post 6.85 earnings per share for the current fiscal year.
Insider Activity
In related news, EVP Bryan Supran sold 1,758 shares of the firm’s stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $226.88, for a total value of $398,855.04. Following the completion of the transaction, the executive vice president owned 12,807 shares in the company, valued at $2,905,652.16. This trade represents a 12.07% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.86% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Alnylam Pharmaceuticals
A number of institutional investors have recently added to or reduced their stakes in ALNY. Toth Financial Advisory Corp bought a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter worth $25,000. Keating Financial Advisory Services Inc. acquired a new stake in Alnylam Pharmaceuticals in the 2nd quarter valued at $42,000. Burkett Financial Services LLC acquired a new stake in Alnylam Pharmaceuticals in the 3rd quarter valued at $37,000. CoreCap Advisors LLC increased its stake in Alnylam Pharmaceuticals by 744.4% during the 3rd quarter. CoreCap Advisors LLC now owns 152 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 134 shares in the last quarter. Finally, Root Financial Partners LLC bought a new stake in Alnylam Pharmaceuticals during the 3rd quarter valued at $48,000. 92.97% of the stock is owned by institutional investors.
Trending Headlines about Alnylam Pharmaceuticals
These are some of the ALNY headlines that stood out recently:
- Neutral Sentiment: One article argues ALNY looks undervalued after a steep share decline. That view could attract value-oriented buyers, but it is an opinion and does not itself establish a near-term catalyst. Article: Alnylam (ALNY) Stock Looks Undervalued As Shares Fell 68%
- Negative Sentiment: Cantor Fitzgerald lowered its expectations for Alnylam, adding to concerns about the stock’s outlook. The available report does not specify the revised estimate or rationale. Article: Cantor Fitzgerald Has Lowered Expectations for Alnylam Pharmaceuticals Stock Price
- Negative Sentiment: Pomerantz LLP said it is investigating potential claims on behalf of Alnylam investors. An investigation is not a finding of wrongdoing, but the news may add legal and reputational uncertainty. Article: Pomerantz Law Firm Investigates Claims on Behalf of Alnylam Investors
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi), a biological process that can reduce the production of specific disease-causing proteins. Founded in 2002 and headquartered in Cambridge, Massachusetts, the company helped advance RNAi from a scientific discovery into a therapeutic approach. Its marketed medicines include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.
Further Reading
- Five stocks we like better than Alnylam Pharmaceuticals
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
